Drug updated on 11/14/2023
| Dosage Form | Liquid (oral: 100% w/w of triheptanoin) |
| Drug Class | Medium-chain triglycerides |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Dojolvi (triheptanoin) Prescribing Information. | 2021 | Ultragenyx Pharmaceutical Inc., Novato, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical and pharmacoeconoic combined report: triheptanoin (Dojolvi). | 2021 | CADTH |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): an evidence- and consensus-based approach. | 2020 | Molecular Genetics and Metabolism |